Results 301 to 310 of about 383,789 (365)

Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production. [PDF]

Anim Cells Syst (Seoul)
Roh G, Lee J, Park HM, Kwak W, Park HJ, Oh A, Na Y, Ha D, Lee YS, Bae SH, Lee S, Yoon S, Lee S, Jung J, Lee J, Nam JH.   +15 more
europepmc   +1 more source

Self‐Photosensitizing Cobalt Complexes for Photocatalytic CO2 Reduction Coupled with CH3OH Oxidation

Angewandte Chemie, EarlyView.
Self‐photosensitizing non‐noble metal complexes achieve CO2 photoreduction coupled with CH3OH photooxidation, simultaneously synthesizing formic acid in the absence of any additional photosensitizers and electron sacrificial reductants. Abstract The use of metal complexes as homogeneous molecular catalysts has attracted considerable attention regarding
Ji‐Hong Zhang, Zhao‐Ming Ge, Di‐Chang Zhong, Jing‐Lin Zuo, Marc Robert, Tong‐Bu Lu   +5 more
wiley   +1 more source

Unraveling the mechanisms of irAEs in endometrial cancer immunotherapy: insights from FAERS and scRNA-seq data. [PDF]

Sci Rep
Zhang L, Yang M, Zhang Y, Lan J, Chen Q.
europepmc   +1 more source

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China. [PDF]

Front Public Health
Chen F, Feng X, Xiao LL, Tang HJ, Qin SX, Peng JP, Bai J.   +6 more
europepmc   +1 more source

Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment study. [PDF]

BMC Cancer
Arpino G, De Angelis C, Gerratana L, Lambertini M, Igidbashian S, Gramigna R, Guillaume X.   +6 more
europepmc   +1 more source

The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database. [PDF]

BMC Cancer
Li S, Huang Z, Zhong X, Zhou Y, Jiang H.
europepmc   +1 more source

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers. [PDF]

J Immunother Cancer
Morgan C, Kurland J, Patel M, O'Brien C, Concepcion P, Doherty GJ, Hois S, Negro A, Pavlovic D, Robbins KA.   +9 more
europepmc   +1 more source

Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs: A Systematic Review.

JAMA Netw Open
Zhao M, Shao T, Yin Y, Fang H, Shao H, Tang W.   +5 more
europepmc   +1 more source